Market Overview

Regeneron Shares Fall Following BMO's Note Of Roche Preference

Related REGN
UPDATE: Bank Of America Reiterates On Regeneron Pharmaceuticals Following Several Positive Catalysts
UPDATE: Brean Capital Reiterates On Regeneron Pharmaceuticals On Increased Confidence
Making Money With Charles Payne: 10/31/14 (Fox Business)

Shares of Regeneron Pharmaceuticals (NASDAQ: REGN) are down three percent following BMO analyst Jim Birchenough's note of customers cost preference of Roche's Avastin.

Birchenough remarked that there has been “broad reconsideration” of use of “low-cost” Avastin over Regeneron's Eylea by patients. The analyst noted that roughly 10 percent of Eylea patients at an investigator's clinic are being switched back to Avastin.

BMO reported that there has been increased inquiry into brand anti-VEGF therapy over Avastin, with “brand therapy becoming harder to justify for stable patients with lower visual acuity.”

Shares of Regeneron closed at $297.69 on Thursday. The stock fell as much as 5.1 percent to $282.52 in Friday's morning trading.

Latest Ratings for REGN

DateFirmActionFromTo
Nov 2014Bank of AmericaMaintainsBuy
Nov 2014Brean CapitalMaintainsBuy
Nov 2014Argus ResearchMaintainsBuy

View More Analyst Ratings for REGN
View the Latest Analyst Ratings

Posted-In: BMO Jim BirchenoughAnalyst Color Short Ideas Analyst Ratings Trading Ideas

 

Related Articles (REGN)

Around the Web, We're Loving...

Get Benzinga's Newsletters